Evaluation of Amiodarone Administration in Patients with New-Onset Atrial Fibrillation in Septic Shock

Q4 Medicine
Medicina Pub Date : 2024-09-02 DOI:10.3390/medicina60091436
Andreea Oprea, Virginia Marina, Oana Roxana Ciobotaru, Cristina-Mihaela Popescu
{"title":"Evaluation of Amiodarone Administration in Patients with New-Onset Atrial Fibrillation in Septic Shock","authors":"Andreea Oprea, Virginia Marina, Oana Roxana Ciobotaru, Cristina-Mihaela Popescu","doi":"10.3390/medicina60091436","DOIUrl":null,"url":null,"abstract":"Background and Objective: New-onset atrial fibrillation (NOAF) is a common cardiac condition often observed in intensive care units. When amiodarone is used to treat this condition, either to maintain sinus rhythm after electrical cardioversion or to control heart rate, complications can arise when a systemic pathology is present. Systemic pathology can result in a decrease in cardiac output and blood pressure, making the management of NOAF and septic shock challenging. Limited international research exists on the coexistence of NOAF and septic shock, making it difficult to determine the optimal course of treatment. While amiodarone is not the primary choice of antiarrhythmic drug for patients in septic shock, it may be considered for those with underlying cardiac issues. This paper aims to investigate the safety of administering amiodarone to patients with septic shock and explore whether another antiarrhythmic drug may be more effective, especially considering the cardiac conditions that patients may have. Materials and Methods: To write this article, we searched electronic databases for studies where authors used amiodarone and other medications for heart rate control or sinus rhythm restoration. Results: The studies reviewed in this work have shown that for the patients with septic shock and NOAF along with a pre-existing cardiac condition like a dilated left atrium, the use of amiodarone may provide greater benefits compared to other antiarrhythmic drugs. For patients with NOAF and septic shock without underlying heart disease, the initial use of propafenone has been found to be advantageous. However, a challenge arises when deciding between rhythm or heart rate control using various drug classes. Unfortunately, there is limited literature available on this specific scenario. Conclusions: NOAF is a frequent and potentially life-threatening complication occurring in one out of seven patients with sepsis, and its incidence is rising among patients with septic shock.","PeriodicalId":18512,"journal":{"name":"Medicina","volume":"161 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/medicina60091436","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background and Objective: New-onset atrial fibrillation (NOAF) is a common cardiac condition often observed in intensive care units. When amiodarone is used to treat this condition, either to maintain sinus rhythm after electrical cardioversion or to control heart rate, complications can arise when a systemic pathology is present. Systemic pathology can result in a decrease in cardiac output and blood pressure, making the management of NOAF and septic shock challenging. Limited international research exists on the coexistence of NOAF and septic shock, making it difficult to determine the optimal course of treatment. While amiodarone is not the primary choice of antiarrhythmic drug for patients in septic shock, it may be considered for those with underlying cardiac issues. This paper aims to investigate the safety of administering amiodarone to patients with septic shock and explore whether another antiarrhythmic drug may be more effective, especially considering the cardiac conditions that patients may have. Materials and Methods: To write this article, we searched electronic databases for studies where authors used amiodarone and other medications for heart rate control or sinus rhythm restoration. Results: The studies reviewed in this work have shown that for the patients with septic shock and NOAF along with a pre-existing cardiac condition like a dilated left atrium, the use of amiodarone may provide greater benefits compared to other antiarrhythmic drugs. For patients with NOAF and septic shock without underlying heart disease, the initial use of propafenone has been found to be advantageous. However, a challenge arises when deciding between rhythm or heart rate control using various drug classes. Unfortunately, there is limited literature available on this specific scenario. Conclusions: NOAF is a frequent and potentially life-threatening complication occurring in one out of seven patients with sepsis, and its incidence is rising among patients with septic shock.
对脓毒性休克新发心房颤动患者服用胺碘酮的评估
背景和目的:新发心房颤动(NOAF)是重症监护病房常见的心脏疾病。使用胺碘酮治疗这种病症时,无论是为了在电复律后维持窦性心律,还是为了控制心率,如果存在全身性病变,都可能出现并发症。全身性病变可导致心输出量和血压下降,使 NOAF 和脓毒性休克的治疗面临挑战。国际上对 NOAF 和脓毒性休克并存的研究有限,因此很难确定最佳治疗方案。虽然胺碘酮不是脓毒性休克患者抗心律失常药物的首选,但对于那些有潜在心脏问题的患者,可以考虑使用胺碘酮。本文旨在研究脓毒性休克患者使用胺碘酮的安全性,并探讨是否其他抗心律失常药物可能更有效,尤其是考虑到患者可能存在的心脏疾病。材料与方法:为了撰写本文,我们在电子数据库中搜索了作者使用胺碘酮和其他药物控制心率或恢复窦性心律的研究。结果本文回顾的研究表明,对于脓毒性休克、NOAF 以及左心房扩张等原有心脏疾病的患者,使用胺碘酮可能比使用其他抗心律失常药物更有效。对于无潜在心脏病的 NOAF 和脓毒性休克患者,最初使用普罗帕酮具有优势。然而,在决定使用不同类别的药物来控制心律或心率时会遇到挑战。遗憾的是,有关这种特殊情况的文献资料十分有限。结论每七名脓毒症患者中就有一名会出现 NOAF,这是一种常见的、可能危及生命的并发症,而且其在脓毒性休克患者中的发生率正在上升。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Medicina
Medicina Medicine-Medicine (all)
CiteScore
0.10
自引率
0.00%
发文量
66
审稿时长
24 weeks
期刊介绍: Publicada con el apoyo del Ministerio de Ciencia, Tecnología e Innovación Productiva. Medicina no tiene propósitos comerciales. El objeto de su creación ha sido propender al adelanto de la medicina argentina. Los beneficios que pudieran obtenerse serán aplicados exclusivamente a ese fin.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信